AmbioPharm Breaks Ground On $28M Expansion Of Pharmaceutical Manufacturing Site In Shanghai

AmbioPharm, a leading U.S.-based pharmaceutical services company specializing in peptide manufacturing, announces the groundbreaking of a 70,000 square-foot capacity expansion project at its Shanghai manufacturing site, marking a major investment in expanding its global manufacturing capabilities. This $28M project reflects the company’s commitment to serving growing global demand and confidence in China’s vital role in the global pharmaceutical supply chain.

The expansion in Building 2 will feature state-of-the-art fragment-based peptide synthesis capabilities with multiple 1000L to 3000L solid-phase and liquid-phase peptide synthesis equipment lines. Once completed, the new space will add significant manufacturing capacity, with the capability to produce over 8 metric tons of crude peptide annually. This output will be further processed utilizing existing downstream peptide purification and isolation capabilities already available at the Shanghai site and to a greater extent at AmbioPharm’s U.S. manufacturing site in North Augusta, South Carolina.

“This expansion underscores our commitment to China and its role in our global operations”, said Brian Gregg, CEO of AmbioPharm. “Our new capabilities will allow us to meet the growing demand for therapeutic peptides and enhance our ability to serve customers throughout the world.”

With a skilled and dedicated workforce, AmbioPharm has a longstanding presence in China and has worked closely with local partners and government officials to bring the expansion project to life. The new manufacturing capacity is expected to be operational in the second half of 2025.

AmbioPharm extends its gratitude to the officials and partners whose support made this expansion possible and who share our vision for sustainable growth and opportunity creation in Shanghai.